ArticleJournal of family medicine and primary care2025
Clinical profile and Mass Drug Administration coverage in patients with lymphatic filariasis: A descriptive study.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Lymphatic filariasis (LF), a tropical illness caused by mosquito-borne parasites, is a serious public health concern in endemic areas such as Jharkhand, India. The illness continues despite efforts by the World Health Organization and the Mass Drug Administration (MDA). This study aims to investigates the clinical and demographic profiles of patients with LF and assesses coverage of MDA. Methods: This cross-sectional study included 100 patients with LF who presented to the General Surgery Outpatient Department. Interviews, clinical exams, and semi-structured questionnaires were used to obtain information about sociodemographic profile, clinical symptoms and MDA coverage. Descriptive statistics and Chi-square tests were used to find the association between clinical profile, drug consumption, and sociodemographic profiles. Results: The study revealed that participants were mostly middle-aged, married (55%), from low-income families (86%), and had varied degrees of hydrocele and lymphedema, with nearly 70% experiencing scrotal enlargement. Furthermore, 44% of patients reported insufficient MDA coverage. There were significant connections found between the size of the hydrocele ( Conclusions: The study highlights important clinical, sociodemographic patterns, and reveal MDA coverage gaps among patients with LF. There is a need of targeted education and enhanced treatment access to improve MDA effectiveness and achieving LF eradication by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.